文献速递胃肠外科围术期管理与 ERAS

腹腔镜肿瘤细胞减灭术联合HIPEC的配对比较分析

Laparoscopic cytoreductive surgery and HIPEC: a comparative matched analysis.
PubMed 文献 · Surg Endosc · 2020-04-23

本研究基于2009年1月至2019年7月前瞻性数据库的回顾性分析,纳入825例不同来源腹膜转移患者,比较腹腔镜与开腹肿瘤细胞减灭术联合HIPEC的术后结局与生存。匹配后腹腔镜组18例、开腹组42例,腹腔镜组住院更短、恢复化疗更早,围术期并发症与早期肿瘤学结果无显著差异。

要点

  • 高度选择患者中腹腔镜CRS+HIPEC可行且安全
  • 腹腔镜组住院时间与恢复化疗时间更短
  • 围术期并发症与早期肿瘤学结果无显著差异

核心结论

  • 高度选择患者中腹腔镜CRS+HIPEC可行且安全,围术期并发症与早期肿瘤学结果无显著差异。
  • 腹腔镜手术患者住院时间更短且恢复辅助化疗更早。
  • 需进一步研究确认微创方式处理腹膜转移的获益。

研究设计与样本

  • 回顾性研究,来自三级转诊医院前瞻性数据库,2009年1月至2019年7月。
  • 纳入825例不同肿瘤来源腹膜转移患者。
  • 比较腹腔镜组(n=18)与符合相同选择标准的匹配开腹组(n=42)。
  • 分析术后结局与生存结果。

主要发现

  • 两组术前与术中特征具有同质性。
  • 腹腔镜组住院时间中位4(2-10)天,开腹组中位9(2-19)天。
  • 腹腔镜组恢复化疗等待时间中位4(3-7)周,开腹组中位8(4-36)周。
  • 围术期输血需求、手术时间及术后并发症与死亡率无差异。
  • 腹腔镜组无早期局部区域复发,短期无病生存两组无差异。

临床怎么用

  • 对高度选择的局限性腹膜疾病患者可考虑腹腔镜CRS+HIPEC。
  • 腹腔镜方式可能缩短住院并提前恢复辅助化疗。
  • 需严格把握选择标准,尚需进一步研究确认获益。

局限性

  • 回顾性研究设计。
  • 腹腔镜组样本量较小(n=18)。
  • 仅纳入高度选择患者,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) is a procedure that has had encouraging results for peritoneal metastases (PM) from diverse tumour origins, but it is not exempt from high morbidity. Recently, the important role of laparoscopy in oncologic surgeries and its benefits have been evaluated for CRS + HIPEC in selected patients, which has yielded promising results. The aim of our study is to analyse the use of laparoscopy for CRS + HIPEC in patients with limited peritoneal disease. METHODS: We have conducted a retrospective study from a prospective database in our tertiary referral hospital within the period of January 2009 to July 2019, which includes 825 patients who had PM from varying tumour origins. We have compared the patients treated with the laparoscopic approach (L-CRS-HIPEC) to a matched population who have undergone the open approach (O-CRS-HIPEC) and fulfil the same selection criteria. We have analysed the postoperative outcomes and survival results. RESULTS: We have confirmed the homogeneity between the sample of the O-CRS + HIPEC (n = 42) and the L-CRS + HIPEC (n = 18) regarding preoperative and intraoperative features. The L-CRS + HIPEC group had shorter hospital stays, (median of 4 [2-10] days versus 9 [2-19] days) and reduced wait time to return to chemotherapy (median of 4 [3-7] weeks and a median of 8 [4-36] weeks) than the O-CRS + HIPEC group. No differences were found regarding the need for perioperative blood transfusion, surgery time or postoperative morbi-mortality. No early locoregional relapse occurred in the L-CRS + HIPEC group and short term disease-free survival did not differ between groups. CONCLUSIONS: Laparoscopy for CRS + HIPEC is feasible and safe in highly selected patients, with no significant differences concerning postoperative morbi-mortality or early oncological results. We have found that patients who have undergone laparoscopic operations have shorter hospital stays and that they return to adjuvant chemotherapy sooner. Further investigation is required to confirm the benefits of minimally invasive procedures for the management of PM.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Rodríguez-Ortiz L, Arjona-Sánchez A, Ibañez-Rubio M, et al. Laparoscopic cytoreductive surgery and HIPEC: a comparative matched analysis. Surg Endosc. 2020. PMID: 32328823. doi:10.1007/s00464-020-07572-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。